Biocamp. In favor of
Experience, qualification, competence, development and safety. Combined to research, develop and deliver the best solutions in probiotics and vaccines for poultry production. This is what Biocamp is offering to its customers since it was founded in 1999.
The company is presently active in the national and international poultry market, and is growing as a result of its permanent search for excellence in its products, as well as investments in research and development.
The company has the structure and specialists to strictly follow the standards established in the Good Manufacturing Practices (GMP) certification, as well as the guidelines of the Ministry of Agriculture, Livestock and Food Supply (MAPA) and regulatory agencies. And also, to provide an exclusive and specialized customer service from the very beginning, the first contact, then the sale, delivery and post-sales.
Why be a Biocamp partner
CBM, A VACCINE COMPANY, WAS ESTABLISHED, THE FIRST OF THE BIOCAMP FOUNDERS.
CBM IS SOLD TO MALLINCKRODT (NOW CALLED MSD)
BIOCAMP IS BORN: REGISTRATION AND PRODUCTION OF ADDITIVES FOR ANIMAL FEEDING – PROBIOTICS FROM NORMAL AVIAN GUT FLORA (NAGF)
CNN, A VACCINE COMPANY, IS ESTABLISHED BY BIOCAMP FOUNDERS
CNN IS SOLD TO CEVA SANTÉ ANIMAL
THE PLANT FOR PRODUCTION OF BIOCAMP BIOLOGICALS IS BUILT
PROBIOTICS START TO BE EXPORTED
REGISTRATION FOR BIOLOGICALS PRODUCTION IS OBTAINED
THE CAMPVAC® SG9R LIQUID VACCINE IS LAUNCHED
PROBIOTICS COLOSTRUM® BIO 21 MIX AND COLOSTRUM® BIO 21 LIQUID ARE PRODUCED
RESEARCH ON LIVE AND INACTIVATED SALMONELA PARATYPHOID VACCINES IS STARTED
FREEZE DRIED CAMPVAC® SG9R AND FREEZE DRIED CAMPVAC® MG F ARE LAUNCHED
A NEW AREA IS ACQUIRED TO PROVIDE PHYSICAL SEPARATION BETWEEN THE MANUFACTURING AND ADMINISTRATIVE PLANTS
THE NEW STRUCTURE FOR QUALITY CONTROL OF “IN VIVO” TESTS, BIOLOGICAL ASSAYS LABORATORY (LEBB), IS INAUGURATED
RESEARCH ON PROBIOTICS FOR SWINE AND AQUACULTURE ARE INITIATED
RESEARCH ON PROBIOTICS FOR AQUACULTURE IS INCREASED
RESTRUCTURING OF THE PROBIOTICS PLANT WITH INVESTMENTS IN A STRUCTURE WITH LEADING EDGE TECHNOLOGY
A NEW AREA IS ACQUIRED TO EXPAND THE MANUFACTURING PLANT
THE BIOLOGICAL PRODUCTION AREA IS EXPANDED
NEW RESEARCH & DEVELOPMENT CENTER